Treatment of non-ST-segment elevation myocardial infarction (NSTEMI) with anticoagulant fondaparinux, as compared to low-molecular-weight heparin (LMWH), had a lower risk of major bleeding events and death both in the hospital and after six months. Researchers analyzed data from a Swedish registry that included 40,616 patients with NSTEMI who received in-hospital treatment with fondaparinux or LMWH between September 2006 through June 2010, with follow-up through ...
You have just read an article categorized health
titled Anticoagulant Fondaparinux Linked With Lower Risk of Bleeding, Death Following Heart Attack as Compared to Heparin.
Written by:
editor - Tuesday, February 17, 2015
There are currently no comments for "Anticoagulant Fondaparinux Linked With Lower Risk of Bleeding, Death Following Heart Attack as Compared to Heparin"
Post a Comment